Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Efinaconazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Almirall Completes Approval Process for Efinaconazole in Europe
Details : Jublia (efinaconazole) is a triazole antifungal compound indicated for the treatment of fungal infection of the nail, known as onychomycosis,
Product Name : Jublia
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2024
Lead Product(s) : Efinaconazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirbanibulin
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Almirall’s Klisyri® for Actinic Keratosis on Expanded Facial Areas
Details : KLISYRI (tirbanibulin) is an approved microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.
Product Name : Klisyri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2024
Lead Product(s) : Tirbanibulin
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALM223
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALM223 (IL-2 mu-Fc) is a modified version of the protein IL-2 designed to selectively activate Regulatory T cells (Tregs). It is being evaluated in Phase I clinical studies for the patients related to Autoinmune dermatology.
Product Name : ALM223
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 21, 2023
Lead Product(s) : ALM223
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tildrakizumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Almirall, The First to Assess Wellbeing in a Dermatology Clinical Study
Details : Ilumetri (tildrakizumab) is a humanized mAb that targets the p19 subunit of IL-23 and inhibits the release of proinflammatory cytokines and chemokines with limited impact on the rest of the immune system. It is indicated for adults with moderate-to-sever...
Product Name : Ilumetri
Product Type : Antibody
Upfront Cash : Inapplicable
December 04, 2023
Lead Product(s) : Tildrakizumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ebglyss (lebrikizumab) is a monoclonal antibody that binds IL-13 with high affinity to specifically prevent the formation of the IL-13Rα1/IL-4Rα heterodimer complex. It is approved for the treatment of moderate-to-severe atopic dermatitis.
Product Name : Ebglyss
Product Type : Antibody
Upfront Cash : Inapplicable
November 17, 2023
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
Details : Ebglyss (lebrikizumab) is an investigational, monoclonal antibody that binds IL-13, which is received positive CHMP opinion for moderate-to-severe atopic dermatitis.
Product Name : Ebglyss
Product Type : Antibody
Upfront Cash : Inapplicable
September 15, 2023
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sarecycline
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SEYSARA (sarecycline) tablet is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.
Product Name : Seysara
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2022
Lead Product(s) : Sarecycline
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirbanibulin
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KLISYRI (tirbanibulin) met key clinical criteria required for its inclusion with 49% of KLISYRI patients achieving complete clearance (100%) of lesions (9% for vehicle) and no patients withdrew from clinical trials due to adverse events.
Product Name : Klisyri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2022
Lead Product(s) : Tirbanibulin
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirbanibulin
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Athenex
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Klisyri® (tirbanibulin) is a novel, topical first-in-class microtubule inhibitor with a selective antiproliferative mechanism of action that we believe represents a significant step forward in the treatment of actinic keratosis (AK) of the face and scal...
Product Name : Klisyri
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 27, 2021
Lead Product(s) : Tirbanibulin
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Athenex
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the initial 16-week placebo-controlled period of ADvocate 1 and ADvocate 2, the incidence of treatment-emergent adverse events (AEs) and serious AEs among patients treated with lebrikizumab was consistent with that of the previous Phase 2 lebrikizumab...
Product Name : Ebglyss
Product Type : Antibody
Upfront Cash : Inapplicable
August 16, 2021
Lead Product(s) : Lebrikizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable